OMEGA THERAPEUTICS IN

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

31 Oct 2023 06:00:16 By Nasdaq GlobeNewswire

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

16 Oct 2023 06:00:46 By Nasdaq GlobeNewswire

Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023

11 Oct 2023 15:00:14 By Nasdaq GlobeNewswire

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 15:00:05 By Nasdaq GlobeNewswire

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

26 Sep 2023 06:00:11 By Nasdaq GlobeNewswire

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

25 Sep 2023 15:00:32 By Nasdaq GlobeNewswire

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

21 Sep 2023 15:00:08 By Nasdaq GlobeNewswire

Omega Therapeutics Announces Updates to its Board of Directors

29 Aug 2023 06:00:52 By Nasdaq GlobeNewswire

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

03 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Omega Therapeutics Appoints Chris Schade to its Board of Directors

12 Jul 2023 06:00:36 By Nasdaq GlobeNewswire

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

01 Jun 2023 06:00:12 By Nasdaq GlobeNewswire

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

31 May 2023 06:00:18 By Nasdaq GlobeNewswire

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

04 May 2023 06:00:07 By Nasdaq GlobeNewswire

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

27 Apr 2023 06:00:31 By Nasdaq GlobeNewswire

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

30 Mar 2023 06:00:49 By Nasdaq GlobeNewswire

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

01 Mar 2023 06:00:14 By Nasdaq GlobeNewswire

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

23 Feb 2023 06:00:51 By Nasdaq GlobeNewswire

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

17 Jan 2023 06:00:13 By Nasdaq GlobeNewswire